View Featured Offers >>

Cell Signaling Technology, Inc. Announces Introduction of Antibody Important to Breast Cancer Research

Danvers, MA – August 27, 2013 – Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific HER3 rabbit monoclonal antibody (mAb), an important addition for researchers studying HER2-mediated breast, lung and ovarian tumors. Although HER2 has been intensively studied for over 20 years, only recently has it come to light that HER3 may be required for HER2 transformation of normal cells1,2 in at least a subset of cancers. Preclinical research has also recently shown that HER3 activity may be a mechanism by which tumor cells escape inhibition3.

Working under the hood.

CST’s HER3 antibody is a rabbit monoclonal and therefore avoids well known background issues when using mouse antibodies for IHC in mouse xenograft models, which predominate in cancer research. Additionally, extensive testing has confirmed that there is no cross-reactivity with other family members, including EGFR, HER2/ErbB2, and HER4/ErbB4, enabling greater confidence in research results. The primary application for HER3 antibody research is IHC, and CST’s HER3/ErbB3 XP® Rabbit mAb has been validated for IHC as well as Western Blot, Immunofluorescence (IF), and Flow Cytometry.

CST’s Cancer Research Group has been focused on unraveling the signaling networks that underlie various cancers. Using innovative proteomic technologies, the study and analysis of the cancer proteome has identified the EML4-ALK fusion, which has been reported in a subset of patients with breast, colon and non-small cell lung cancer (NSCLC). Patents have been issued (8,486,645, 8,481,279, 8,377,642, 8,288,102, 8,232,060, 8,168,383, and 7,700,339) for EML4-ALK in NSCLC that span from research through diagnosis and therapy.

Founded by research scientists in 1999, Cell Signaling Technology (CST) is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. It’s why we produce all of our antibodies in house, and perform painstaking validations for multiple applications. And the same CST scientists who produce our antibodies also provide technical support for customers, helping them design experiments, troubleshoot, and achieve reliable results. We do this because that’s what we’d want if we were in the lab. Because, actually, we are.

  1. Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 97(4), 453–7.
  2. Campbell MR, Amin D, Moasser MM (2010) HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin. Cancer Res. 16(5), 1373–83.
  3. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126), 437–41.

For any media inquiries please contact:

Rebecca J. Reppucci
Cell Signaling Technology, Inc.
Director of Marketing Communications
phone: +1-978-867-2382
email: [email protected]